Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Blood - Tập 126 - Trang 1762-1769 - 2015
Heinz Gisslinger1, Oleh Zagrijtschuk2, Veronika Buxhofer-Ausch3,4, Josef Thaler5, Ernst Schloegl6, Guenther A. Gastl7, Dominik Wolf7,8, Robert Kralovics1,9, Bettina Gisslinger1, Karin Strecker3, Alexander Egle10, Thomas Melchardt10, Sonja Burgstaller5, Ella Willenbacher7, Martin Schalling1, Nicole C. Them9, Pavla Kadlecova11, Christoph Klade2, Richard Greil10
1Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;
2AOP Orphan Pharmaceuticals AG, Vienna, Austria;
3Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria
4Krankenhaus der Elisabethinen Linz, Linz, Austria
5Department of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria
6Third Medical Department, Hanusch Hospital, Vienna, Austria
7Department of Internal Medicine V, Hematology & Oncology, Innsbruck Medical University, Innsbruck, Austria;
8Medical Clinic 3, Oncology, Hematology and Rheumatology, University Hospital of Bonn, Bonn, Germany;
9Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
10Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; and
11Advanced Drug and Device Services SAS, Brno, Czech Republic

Tóm tắt

Key Points The novel IFNα-2b, ropeginterferon alfa-2b, administered once every 2 weeks has low toxicity and induces high and sustained response rates in polycythemia vera patients. Ropeginterferon alfa-2b induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.

Tài liệu tham khảo